JPWO2006082649A1 - 多嚢胞性卵巣症候群(pcos)治療剤 - Google Patents
多嚢胞性卵巣症候群(pcos)治療剤 Download PDFInfo
- Publication number
- JPWO2006082649A1 JPWO2006082649A1 JP2006517881A JP2006517881A JPWO2006082649A1 JP WO2006082649 A1 JPWO2006082649 A1 JP WO2006082649A1 JP 2006517881 A JP2006517881 A JP 2006517881A JP 2006517881 A JP2006517881 A JP 2006517881A JP WO2006082649 A1 JPWO2006082649 A1 JP WO2006082649A1
- Authority
- JP
- Japan
- Prior art keywords
- mushroom
- pcos
- extract
- polycystic ovary
- ovary syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 67
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 59
- 239000000284 extract Substances 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 20
- 240000001080 Grifola frondosa Species 0.000 claims description 17
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 12
- 240000000599 Lentinula edodes Species 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 241000222518 Agaricus Species 0.000 claims description 9
- 240000001462 Pleurotus ostreatus Species 0.000 claims description 9
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims description 9
- 244000183278 Nephelium litchi Species 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 7
- 240000008397 Ganoderma lucidum Species 0.000 claims description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 241000222684 Grifola Species 0.000 claims description 4
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 4
- 241000222355 Trametes versicolor Species 0.000 claims description 4
- 244000028550 Auricularia auricula Species 0.000 claims description 3
- 235000000023 Auricularia auricula Nutrition 0.000 claims description 3
- 241000123150 Fomitopsis pinicola Species 0.000 claims description 3
- 241001149422 Ganoderma applanatum Species 0.000 claims description 3
- 241000207199 Citrus Species 0.000 claims description 2
- 240000008067 Cucumis sativus Species 0.000 claims description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 2
- 241000289667 Erinaceus Species 0.000 claims description 2
- 244000097863 Grifola umbellata Species 0.000 claims description 2
- 235000002897 Grifola umbellata Nutrition 0.000 claims description 2
- 241000222418 Lentinus Species 0.000 claims description 2
- 241000222350 Pleurotus Species 0.000 claims description 2
- 235000020971 citrus fruits Nutrition 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 claims 1
- 244000171085 Polyporus umbellatus Species 0.000 claims 1
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 201000005670 Anovulation Diseases 0.000 abstract description 4
- 206010002659 Anovulatory cycle Diseases 0.000 abstract description 4
- 231100000552 anovulation Toxicity 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 description 31
- 229940075071 maitake extract Drugs 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000016087 ovulation Effects 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 102000003886 Glycoproteins Human genes 0.000 description 10
- 108090000288 Glycoproteins Proteins 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000013543 active substance Substances 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000009181 shakuyaku-kanzoh-toh Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 5
- 102000006771 Gonadotropins Human genes 0.000 description 5
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000002622 gonadotropin Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229960003608 clomifene Drugs 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108010057021 Menotropins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940127234 oral contraceptive Drugs 0.000 description 3
- 239000003539 oral contraceptive agent Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- -1 sucrose fatty acid ester Chemical class 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 description 2
- 208000034702 Multiple pregnancies Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 244000252132 Pleurotus eryngii Species 0.000 description 2
- 241000222341 Polyporaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020001775 protein parts Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001327634 Agaricus blazei Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000357408 Ophiocordyceps sobolifera Species 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000908178 Tremella fuciformis Species 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 231100000551 menstrual abnormality Toxicity 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
クロミフェンが視床下部に働きかけて、排卵を起こさせる治療法であるが、排卵が起らない場合がある。
クロミフェンだけの投与で効果が見られない場合、クロミフェンにステロイドホルモンやHMG(ヒト閉経ゴナドトロピン:Human menopausal gonadotropins)などの薬剤を併用する治療法である。
性腺刺激ホルモン(ゴナドトロピン)を患者に注射し、卵巣を刺激して排卵を誘発する治療法である。この治療法は、効果が比較的高く、妊娠率も良好であるが、多胎妊娠や卵巣過剰刺激症候群(OHSS:Ovarian hyperstimulation syndrome)といった副作用を発症しやすい問題点がある。
漢方薬の一種である芍薬甘草湯を投与する治療法であり、副作用がほとんどないが、充分に満足できる効果を挙げていない問題点がある。
腹腔鏡を用いて卵巣の表面にレーザー光線を照射し、小さな孔を開ける治療法である。根治的な治療法ではなく、生体に対する侵襲が避けられない問題点がある。
挙児(妊娠)を希望しない、未婚や若年の多嚢胞性卵巣症候群(PCOS)の女性には、経口避妊薬などのホルモン剤を用いて、月経を周期的に起こさせるような治療が行なわれている。
[図2]図2は、製造例3で得られたシイタケ抽出物の高速液体クロマトグラフィー(HPLC)の分析結果を示したチャート図である。(製造例3)
[図3]図3は、製造例4で得られたアガリクス抽出物の高速液体クロマトグラフィー(HPLC)の分析結果を示したチャート図である。(製造例4)
[図4]図4は、製造例5で得られたレイシ抽出物の高速液体クロマトグラフィー(HPLC)の分析結果を示したチャート図である。(製造例5)
[図5]図5は、製造例6で得られたヒラタケ抽出物の高速液体クロマトグラフィー(HPLC)の分析結果を示したチャート図である。(製造例6)
乾燥マイタケ子実体粉末1000gに、95%エタノール水5Lを加え、室温で攪拌しながら2〜3時間処理し、濾過によりエタノール可溶性成分を除去した。
上記のようにして得られた精製したマイタケ抽出物について、単純タンパク質部分の定量はBradford法により行なった。単純タンパク質部分の構成アミノ酸の分析については、自動アミノ酸分析装置(Hitachi L−8500A Amino Acid Analyzer)により行なった。また、糖質部分の定量はフェノール硫酸法により行ない、糖質部分の組成は高速液体クロマトグラフィー(HPLC)により行なった。分子量の測定はSDS−PAGE電気泳動により行なった。また、1H−NMR測定も行なった。
外観:褐色、吸湿性粉末
溶解性:水およびアルカリ性溶液に可溶
安定性:高温に安定、エタノールにも安定
化学構成:単純タンパク質部分:糖質部分=75:25〜90:10(表1を参照)
単純タンパク質部分の構成アミノ酸組成:アスパラギン、グルタミン、セリン、スレオニン、グリシン、アラニン、バリン、システイン、メチオニン、イソロイシン、ロイシン、チロシン、フェニルアラニン、リシン、ヒスチジン、アルギニン、プロリン
糖質部分の組成:ガラクトース、マンノース、グルコース、N−アセチルグルコサミン、フコース
1H−NMRスペクトル:3.0473、3.8983、6.8500、7.3150平均分子量:20,000。
製造例1で得たマイタケ抽出物を用いて、以下の組成で錠剤を製造した。
錠剤 錠剤当たり
主成分:
マイタケ抽出物(粉末) 36mg
乾燥マイタケ原料の粉末 250mg
助剤:
微結晶セルロース 264mg
リン酸−水素カルシウム 20mg
ショ糖脂肪酸エステル 20mg
微粒化二酸化ケイ素 10mg
コーティング材:
メチルセルロース 錠剤質量の1〜1.5%
分析項目:
崩壊時間 45分以下
質量差 600mg±5%
衛生検査:
一般生菌数 3000以下
酵母とカビ 300以下
サルモネラ 陰性
大腸菌群 陰性
キノコ類をマイタケに代えて、シイタケ(製造例3)、アガリクス(製造例4)、レイシ(製造例5)、ヒラタケ(製造例6)とした以外は、製造例1と同様にして、キノコ類抽出物を製造した。これらの抽出物について、上記分析例と同様の方法でHPLCの測定を行った。図2にシイタケ抽出物のHPLCの分析結果のチャート図を、図3にアガリクス抽出物のHPLCの分析結果のチャート図を、図4にレイシ抽出物のHPLCの分析結果のチャート図を、図5にヒラタケ抽出物のHPLCの分析結果のチャート図を、それぞれ示す。図2〜5では、製造例1のマイタケ抽出物の7.189とほぼ同じ位置に、すなわちそれぞれ7.087(図2)、7.082(図3)、7.096(図4)、7.086(図5)にピークが見られ、製造例1のマイタケ抽出物と同様の成分が含まれていることが確認された。
多嚢胞性卵巣症候群(PCOS)と診断された外来患者で、3ヶ月以上にわたって無排卵のもの18名を無作為に2群に分けた。試験群には、上記製造例2で製造した錠剤(本発明錠剤)を、1日9錠を3回に分けて投与し、対照群には、芍薬甘草湯を1日7.5gを3回に分けて投与した。それぞれ12週間(3周期)にわたって投与を続け、各群の患者に基礎体温表を記録させ、排卵の有無を確認した。
健康な4週齢のICR系マウスを、雌雄それぞれ10匹づつ用いて安全性試験を行なった。これらマウスにつき絶食後4時間後に体重を測定した後、試験群には、雌雄ともに、製造例1で得たマイタケ抽出物を蒸留水に溶解したものを、2,000mg/kg体重の用量で胃ゾンデを用いて強制単回投与した。対照群には、雄で0.7mL,雌で0.6mLの純水を同様に投与した。観察期間は14日間とし、観察期間終了後にすべて剖検した。
Claims (5)
- キノコ類の抽出物を有効成分とする多嚢胞性卵巣症候群(PCOS)治療剤。
- 前記キノコ類が、マイタケ(Grifola frondosa)、チョレイマイタケ(Polyporus umbellatus)、トンビマイタケ(Meripilus giganteus)、白マイタケ(Grifola albicans)、シイタケ(Lentinus edodes)、アガリクス(Agaricus blazei Murill)、マッシュルーム(Agaricus bispirus)、コフキサルノコシカケ(Ganoderma applanatum)、ツガサルノコシカケ(Fomitopsis pinicola)、カワラタケ(Coriolus versicolor)、レイシ(Ganoderma lucidum)、ヒラタケ(Pleurotus ostreatus)、エリンギ(Pleurotus eryngii)、ヤマブシタケ(Hericium erinaceus)、冬虫夏草(Cordyceps sinensis)、セミタケ(Cordyceps sobolifera)、キクラゲ(Auricularia auricula)、シロキクラゲ(Tremella fuciformis)、およびメシマコブ(Phellinus linteus)からなる群より選ばれる1種以上である請求項1に記載の多嚢胞性卵巣症候群(PCOS)治療剤。
- 前記キノコ類が、マイタケ、シイタケ、アガリクス、レイシ、およびヒラタケからなる群より選ばれる1種以上である請求項1に記載の多嚢胞性卵巣症候群(PCOS)治療剤。
- 前記キノコ類が、マイタケである請求項1に記載の多嚢胞性卵巣症候群(PCOS)治療剤。
- 前記キノコ類の抽出物が、
(1)前記キノコ類原料を濃度90%以上のエタノールで処理し、エタノール可溶性成分を除去する工程、
(2)その後、熱水抽出を行ない、得られた熱水抽出液に最終容量濃度が50〜75%になるまでエタノールを加え、生成した不溶性成分を除去し、上澄液を得る工程、
(3)得られた上澄液から、分子量14,000以上の画分を収集する工程、を含む工程により製造されるものである請求項1〜4のいずれか1項に記載の多嚢胞性卵巣症候群(PCOS)治療剤。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2005/001697 WO2006082649A1 (ja) | 2005-02-04 | 2005-02-04 | 多嚢胞性卵巣症候群(pcos)治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006082649A1 true JPWO2006082649A1 (ja) | 2008-10-23 |
JP4464964B2 JP4464964B2 (ja) | 2010-05-19 |
Family
ID=36777044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006517881A Active JP4464964B2 (ja) | 2005-02-04 | 2005-02-04 | 多嚢胞性卵巣症候群(pcos)治療剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4464964B2 (ja) |
CA (1) | CA2590549C (ja) |
WO (1) | WO2006082649A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4233029B2 (ja) | 2003-08-27 | 2009-03-04 | 白田 正樹 | マイタケ由来の抽出物およびグリコプロテイン並びにその製造方法 |
US20150150293A1 (en) * | 2012-05-16 | 2015-06-04 | A School Corporation Kansai University | Method for producing enokitake mushroom extract, enokitake mushroom extract, and food additive |
CN104689070A (zh) * | 2015-02-26 | 2015-06-10 | 魏代淑 | 一种治疗多囊卵巢综合征无排卵症的中药制剂 |
CN105148119A (zh) * | 2015-10-02 | 2015-12-16 | 南京多宝生物科技有限公司 | 一种用于治疗多囊卵巢综合征的药物制剂 |
CN115778932B (zh) * | 2023-02-02 | 2023-11-21 | 北京大学第三医院(北京大学第三临床医学院) | 一种低支链氨基酸组合物在制备治疗多囊卵巢综合征的药物中的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004300104A (ja) * | 2003-04-01 | 2004-10-28 | Nasu Bio Farm:Kk | 女性ホルモン不足症治療剤 |
-
2005
- 2005-02-04 JP JP2006517881A patent/JP4464964B2/ja active Active
- 2005-02-04 CA CA2590549A patent/CA2590549C/en active Active
- 2005-02-04 WO PCT/JP2005/001697 patent/WO2006082649A1/ja not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2590549A1 (en) | 2006-08-10 |
CA2590549C (en) | 2013-07-02 |
JP4464964B2 (ja) | 2010-05-19 |
WO2006082649A1 (ja) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8168198B2 (en) | Therapeutic agent for polycystic ovary syndrome (PCOS) | |
US6783771B2 (en) | Physiologically active substance EEM-S originating in mushrooms, process for producing the same and drugs | |
EP3141255B1 (en) | Memory improving composition, preparation method and use thereof | |
EP1092765A2 (en) | Germination-activated red Ganoderma lucidum spores and method for producing the same | |
JP4464964B2 (ja) | 多嚢胞性卵巣症候群(pcos)治療剤 | |
JP6656316B2 (ja) | ハマナツメの使用方法、ハマナツメ抽出物の使用方法及び薬物混合物の使用方法 | |
JPS6325600B2 (ja) | ||
US6953580B2 (en) | Composition having physiological activity and production method thereof | |
US6726932B2 (en) | Fatty acid-containing composition | |
US20230364169A1 (en) | Use of antrodia cinnamomea for increasing alcohol metabolism or/and hangover | |
JPS6219525A (ja) | 植物起源の生物活性物質の製造法および同物質含有組成物 | |
JP2004344079A (ja) | チャーガを含有する健康補助食品 | |
CN105963330B (zh) | 神秘果制剂及其应用 | |
US7214778B2 (en) | Glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from Grifola frondosa, and a method for preparing same | |
KR20020069269A (ko) | 담자균류 및 두릅나무과 추출물의 생리학적 활성 조성물 | |
JP4323128B2 (ja) | 生理活性組成物 | |
JPH11152230A (ja) | 茸またはその抽出物を含有する組成物 | |
EP1398036B1 (en) | Ganoderma lucidum spores for treatment of systemic lupus erytrhomatosus (SLE) | |
JP2009024027A (ja) | 生理活性組成物 | |
JP2001064195A (ja) | 茸類及び/または酵母類から生理活性物質を採取する方法及びそれらの生理活性剤。 | |
US8247006B2 (en) | Composition and method of treating lipid encapsulated virus infections | |
CN111011609A (zh) | 一种用于增强哺乳动物的免疫力的组合物 | |
KR100446061B1 (ko) | 유기용매흡착성 생약 미립구를 포함하는 숙취경감용 약학조성물 및 건강 보조식품 | |
KR950012622B1 (ko) | 버섯추출물을 함유한 건강식품 | |
JPH0769913A (ja) | Aids症改善効果を有する物質の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090826 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091203 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100202 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100219 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130226 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4464964 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |